Dallas and Washington D.C. – In a significant step forward for the diagnosis and treatment of a potentially life-threatening condition, the American Heart Association (AHA) and the American College of Cardiology (ACC) have jointly released comprehensive guidelines for the evaluation and management of acute pulmonary embolism (PE). Published February 19, 2026, in Circulation and JACC, the new guidelines aim to standardize care and improve outcomes for the approximately 470,000 people hospitalized with PE annually in the U.S. [1, 3].
Pulmonary embolism occurs when a blood clot, typically originating in a deep vein in the leg or pelvis, travels to the lungs and blocks an artery. This can lead to reduced oxygen levels, lung damage, and strain on the heart, making it a medical emergency. The updated guidelines reflect significant advances in understanding PE and its treatment, providing clinicians with a roadmap for navigating these developments [3].
A key component of the new guidelines is the introduction of the AHA/ACC Acute Pulmonary Embolism Clinical Categories – a system designed to categorize the severity and prognosis of PE, ranging from low to high risk for adverse outcomes [1, 5]. These categories, labeled A through E with subcategories, are intended to enhance the precision of severity classification and aid in evidence-based therapeutic decision-making [2, 5].
The guidelines recommend hospitalization for symptomatic patients with elevated clinical severity scores, including those with elevated biomarkers and/or right ventricular dysfunction (AHA/ACC PE Category C), those experiencing incipient cardiopulmonary failure (AHA/ACC PE Category D), and those with cardiopulmonary failure characterized by persistent hypotension (AHA/ACC PE Category E) [2]. Optimizing treatment strategies is the goal for these higher-risk patients.
New Clinical Classification System
The five categories established by the AHA and ACC provide a more nuanced approach to assessing risk. This system allows for a more tailored treatment plan based on the individual patient’s condition. The guidelines emphasize the importance of prompt diagnosis and treatment to improve patient outcomes [3].
Anticoagulation Recommendations
For patients with acute PE who are eligible for oral anticoagulation, the guidelines recommend direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs), unless contraindicated, to prevent recurrent venous thromboembolism (VTE) and reduce major bleeding [2]. This recommendation reflects the growing body of evidence supporting the efficacy and safety of DOACs in this setting.
Mark A. Creager, MD, FACC, FAHA, MSVM, chair of the guideline writing committee, emphasized the importance of these updated recommendations. “There have been significant advances in the understanding of pulmonary embolism and treatments to effectively manage this condition,” he said [3]. “This guideline is a road map to help clinicians navigate these advances for the safest and most effective approaches to care for people with this condition.”
The development of these guidelines involved a comprehensive literature review, examining clinical studies, reviews, and other evidence published between February 2024 and October 2024 [5]. The focus remains on an evidence-based and patient-centered approach to acute PE evaluation and management, encompassing the entire period from symptom onset through clinical follow-up [5].
As research continues and new data emerges, these guidelines will likely be refined. Though, they represent a crucial step towards improving the care of patients with acute pulmonary embolism and reducing the significant morbidity and mortality associated with this condition.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
What are your thoughts on these new guidelines? Share your comments below, and please share this article with your network.
